ClinicalTrials.gg
RecruitingNCT05625581Updated Nov 23, 2022

Tofatib Treatment for IgG4-related Disease

An observational study in IgG4-related Disease, sponsored by Changhai Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-23.

Sponsored by Changhai Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Immunoglobulin G4-Related Disease with a site in China — 24 open to participants now, 28 under way, 5 of them phase 3. Immunoglobulin G4-Related Disease · China.

Started
2022
with 2 others
Observational
4 of 41
3 open now
Primary completion
2024-12
later than 2 of 27 live
Registered
13th of 41
by date
Lead sponsor
2 of 41
Changhai Hospital

Among the 41 studies in Immunoglobulin G4-Related Disease with a site in China, this one is one of 3 that started in 2022, is one of 4 observational ones, reaches primary completion later than 2 of the 27 other live ones, and was the 13th registered.

Immunoglobulin G4-Related Disease

73 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.

Browse Immunoglobulin G4-Related Disease studies →

Open to participants now

24 of the 41 studies in Immunoglobulin G4-Related Disease with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Immunoglobulin G4-Related Disease studies recruiting now, 11 (41%) set no upper age limit and 13 (48%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Immunoglobulin G4-Related Disease with a site in China, or all of them as a file.
02

Study summary

Compared with cyclophosphamide, the efficacy and safety of tofacitinib in the treatment of active IgG4-related diseases were evaluated.

Read the detailed description

This study is a prospective, single center, non randomized, controlled, open label clinical observation study to evaluate the efficacy and safety of tropitib versus cyclophosphamide in inducing remission in IgG4-RD patients.

  1. Investigators observe the diagnosis and treatment of IgG4-RD patients, and only provide patients with clinically appropriate diagnosis and treatment proposals.

It does not interfere with the choice of treatment plan for patients with the study drug of tropib or cyclophosphamide. If the patient chooses the hormone combined with tofatib or the hormone combined with cyclophosphamide as the main treatment drug, and at the same time meets the inclusion and exclusion criteria of this study, the patient can be included in this clinical observation study and become a subject. The experimental group was treated with glucocorticoid combined with tofatib, and the control group was treated with glucocorticoid combined with cyclophosphamide. It is planned that 20 people in each group will be treated for 6 months. After the study, the number of subjects in each group shall be at least 20 according to the actual situation. In the final statistical analysis, ensure that the sample size of the two groups participating in the statistical analysis is controlled at about 1:1.

  1. The primary end point of this study was to compare the remission rate of the two groups after treatment; The secondary end point was to compare the response rate, recurrence rate and adverse event rate of the two groups after treatment.
03

Conditions studied

  • IgG4-related Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

IgG4-RD

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • It meets the 2019 ACR/EULAR classification diagnostic criteria for IgG4 related diseases, and is an active IgG4-RD, defined as an IgG4-RD RI score ≥ 3 points when screening

Exclusion criteria

Exclusion Criteria:

    1. IgG4 related diseases endangering organ function or life;

      1. Only Mikulicz disease, no other internal organs involved;
      1. People with history of thrombotic disease or high risk of thrombosis;
      1. Have a history of malignant tumor;
      1. Active infection;
      1. Pregnant or lactating women;
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Glucocorticosteroids combined with Cyclophosphamide Group

    Glucocorticoid: 0.5-1.0 mg/kg/d prednisone (or other glucocorticoids of equivalent dose) for 1 month (visit V2-V3), then reduced by 5 mg every 2 weeks, and maintained at 5-10 mg/day to visit V8. Cyclophosphamide: intravenous infusion, once a month, 0.5-1g/m2 each time, 6 times in total, until the end of visit V7.

    Drug: tofacitinib

  • Glucocorticoids combined with tofacitinib Group

    Glucocorticoid: 0.5-1.0 mg/kg/d prednisone (or other glucocorticoids of equivalent dose) for 1 month (visit V2-V3), then reduced by 5 mg every 2 weeks, and maintained at 5-10 mg/day to visit V8. Tofacitinib: oral, twice a day, 5mg each time, lasting for 6 months, until the end of visit V8.

    Drug: tofacitinib

Interventions

  • All subjects were treated immediately after non randomized enrollment. The treatment scheme of the experimental group: glucocorticoid+tropitib; the treatment scheme of the control group: glucocorticoid+cyclophosphamide.

    Also known as: cyclophosphamide

06

What researchers measure

Primary outcomes

  1. Disease remission rate at 1 month, 3 months and 6 months of treatment (%)

    Definition of disease remission: including ① complete remission (CR) (main efficacy index), partial remission (PR), continuous complete remission (CCR) and no change (NC).

    Time frame: 1 month, 3 months and 6 months of treatment

Secondary outcomes

  1. Response rate at 1 month, 3 months and 6 months after treatment (%)

    Defined as IgG4-RD RI score decrease ≥ 1 point

    Time frame: 1 month, 3 months and 6 months after treatment

  2. Disease recurrence rate at 3 and 6 months after treatment (%)

    There are two types of disease recurrence, clinical recurrence and serological recurrence. Clinical recurrence was defined as recurrence of clinical symptoms or deterioration of imaging findings, with or without elevated serum IgG4 levels; Serological relapse was defined as an increase in serum IgG4 level and an increase in IgG4-RD RI score of ≥ 1 point after treatment, without recurrence of clinical symptoms or deterioration of imaging manifestations. The isolated increase of serum IgG4 concentration only constitutes serological recurrence. The date of recurrence is the date of onset of symptoms, or the date of new or deteriorated physical examination, laboratory examination or radiological examination results.

    Time frame: 3 and 6 months after treatment

  3. Changes in physician's overall assessment (PGA) from baseline at 1 month, 3 months and 6 months of treatment

    First, the doctor evaluated the overall situation of IgG4 - RD subjects and marked them at the corresponding position of the straight line in the form of a vertical vertical line "l". The straight line is a 100mm scale, where the 0 end of the straight line represents very good, and the 100mm end represents very poor.

    Time frame: 1 month, 3 months and 6 months of treatment

Other outcomes

  1. Changes in the number of organs involved and IgG4-RD RI scores from the baseline after 6 months of treatment

    The IgG4-RD RI value is obtained by superimposing the individual organ/site score of the patient. The score range of each organ/part is 0-3 points, which is defined as follows: 0 point means that the organ/part is not involved or completely relieved; 1: The lesions improved but still existed; 2 points: (after drug withdrawal) there was a new disease or recurrence of the previously involved site, or the disease did not improve after treatment; 3 Divided into (despite treatment) deterioration of lesions or new lesions. \*When the disease of an important affected organ is urgent and requires active treatment, the score of the organ shall be doubled.

    Time frame: 6 months of treatment

  2. Changes of IgG4 level and related immunological indicators from baseline after 6 months of treatment

    Relevant immune indicators include erythrocyte sedimentation rate, CRP, immunoglobulin, complement, IgG4, ANA spectrum, RF, ANCA, lymphocyte subsets, and cellular factor

    Time frame: 6 months of treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2022 (actual). Primary completion is estimated for Dec 2024, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2022
First posted
Nov 23, 2022
StartActual
Nov 10, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2025
Last update
Nov 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05625581
Lead sponsor
Changhai Hospital
Responsible party
Sponsor
First posted
Nov 23, 2022
Start date
Nov 10, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Nov 23, 2022

Study contacts

Gao Jie, doctor
Contact
gaojif@qq.com
13585561861
Gao Jie, doctor
study chair · Changhai Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion